We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Gritstone bio Inc (GRTS) USD0.0001

Sell:$2.12 Buy:$2.13 Change: $0.13 (6.19%)
NASDAQ:0.41%
Market closed |  Prices as at close on 4 March 2024 | Switch to live prices |
Sell:$2.12
Buy:$2.13
Change: $0.13 (6.19%)
Market closed |  Prices as at close on 4 March 2024 | Switch to live prices |
Sell:$2.12
Buy:$2.13
Change: $0.13 (6.19%)
Market closed |  Prices as at close on 4 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.

Contact details

Address:
5959 HORTON STREET, SUITE 300
EMERYVILLE
94608
United States
Telephone:
+1 (510) 8716100
Website:
https://gritstonebio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GRTS
ISIN:
US39868T1051
Market cap:
$192.59 million
Shares in issue:
95.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrew Allen
    President, Chief Executive Officer, Director
  • Vassiliki Economides
    Chief Financial Officer, Executive Vice President
  • Erin Jones
    Chief Operating Officer, Executive Vice President
  • Matthew Hawryluk
    Executive Vice President, Chief Business Officer
  • Karin Jooss
    Executive Vice President, Head of Research and Development
  • Vijay Yabannavar
    Executive Vice President, Chief Technical Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.